GlassScriptPhysician profile
Farrukh M Adhami
NPI 1598766925
$34,691.16
in general payments reported to CMS, 2019-2025
68 companies · $2,327 in 2025
The $2,327 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $919 · 2021: $3,277 · 2022: $5,022 · 2023: $17K · 2024: $3,988 · 2025: $2,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $8,052 · Travel and Lodging: $2,626 · Consulting Fee: $1,250 · Long Term Medical Supply Or Device Loan: $881 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,750.00 |
| Food and Beverage | $8,051.72 |
| Travel and Lodging | $2,626.00 |
| Consulting Fee | $1,250.00 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $18,428.00 | 2021-2024 | |
| Janssen Biotech, INC. | $1,667.31 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,531.46 | 2019-2025 | Kisqali, Piqray |
| Seagen INC. | $1,377.30 | 2020-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $1,172.25 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,065.68 | 2019-2025 | Opdivo, Reblozyl, Eliquis |
| Pfizer INC. | $962.96 | 2019-2025 | |
| Daiichi Sankyo INC. | $700.89 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $595.22 | 2019-2025 | Imfinzi, Enhertu |
| Genzyme Corporation | $542.00 | 2019-2025 | |
| Amgen INC. | $516.16 | 2019-2023 | Lumakras, Kyprolis |
| Genentech USA, INC. | $475.63 | 2019-2025 | Tecentriq, Gavreto, Alecensa |
| Regeneron Healthcare Solutions, INC. | $389.36 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $384.81 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $310.49 | 2021-2025 | Trodelvy |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $304.26 | 2022-2025 | |
| Eisai INC. | $278.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $267.30 | 2019-2023 | Ninlaro |
| Celgene Corporation | $257.43 | 2020-2024 | Pomalyst, Reblozyl, Opdualag |
| Verastem, INC. | $241.91 | 2019 | |
| Aveo Pharmaceuticals, INC. | $241.64 | 2022-2025 | Fotivda |
| Incyte Corporation | $223.10 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Karyopharm Therapeutics INC. | $222.84 | 2021-2025 | Xpovio |
| Kite Pharma, INC. | $205.95 | 2020-2025 | Yescarta |
| Abbvie INC. | $173.73 | 2023-2025 | Venclexta |
| Glaxosmithkline, LLC. | $173.35 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $172.28 | 2019-2025 | Gavreto, Rezlidhia, Tavalisse |
| Foundation Medicine, INC. | $156.38 | 2019-2023 | Foundationone Liquid Cdx |
| Beigene USA, INC. | $131.02 | 2023-2024 | Brukinsa |
| Adc Therapeutics America, INC. | $110.35 | 2023 | |
| Exelixis INC. | $103.24 | 2019-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.45 | 2019-2025 | |
| Array Biopharma INC | $92.06 | 2019-2025 | Mektovi, Braftovi, Xalkori |
| Stemline Therapeutics INC. | $83.96 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $73.90 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $68.54 | 2021-2025 | |
| Legend Biotech USA INC. | $66.93 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $50.83 | 2019-2022 | |
| Genmab U.S., INC. | $50.28 | 2023-2025 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $49.83 | 2020-2022 | |
| Deciphera Pharmaceuticals INC. | $48.59 | 2022-2024 | Qinlock |
| Alexion Pharmaceuticals, INC. | $40.83 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $40.22 | 2023 | Onpattro, Givlaari |
| Lilly USA, LLC | $37.50 | 2019-2022 | |
| Emd Serono, INC. | $33.09 | 2024-2025 | |
| Blueprint Medicines Corporation | $31.99 | 2020-2022 | |
| Syndax Pharmaceuticals, INC. | $31.70 | 2025 | |
| Pharmaessentia USA Corporation | $30.33 | 2023-2024 | Besremi |
| Acrotech Biopharma INC. | $29.96 | 2023-2024 | Beleodaq |
| Morphosys, US INC. | $29.65 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $26.12 | 2025 | Clonoseq |
| Caris Mpi, INC. | $23.18 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $22.89 | 2025 | Loqtorzi |
| Pharming Healthcare, INC. | $22.46 | 2023 | Ruconest |
| Sun Pharmaceutical Industries INC. | $21.84 | 2023 | Odomzo |
| Fennec Pharmaceuticals, INC. | $21.83 | 2025 | Fyarro |
| Acceleron Pharma, INC. | $21.36 | 2021 | |
| Aadi Bioscience, INC. | $19.17 | 2023 | Fyarro |
| Dova Pharmaceuticals | $18.03 | 2021 | |
| Tersera Therapeutics LLC | $17.62 | 2022 | |
| Epizyme, INC. | $16.81 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.69 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.52 | 2021 | |
| Progenics Pharmaceuticals, INC. | $15.60 | 2025 | |
| Tempus Ai, INC | $14.42 | 2024 | |
| Immunomedics, INC. | $13.55 | 2020 | |
| Astellas Pharma US INC | $13.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$70,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrukh Adhami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.